The news that NICE has approved teplizumab, a pioneering treatment to delay the onset of type 1 diabetes, brings new hope for thousands of individuals at high risk. This breakthrough recommendation means that the NHS will now be able to prescribe the medication to those aged eight and over who are in stage 2 of the condition – effectively slowing down the progression of the disease.
Type 1 diabetes is an autoimmune condition where the body's immune system mistakenly attacks the insulin-producing beta cells in the pancreas. Current treatment options involve lifelong insulin injections, but teplizumab (marketed as Tzield) works differently: it targets specific immune cells to help preserve these vital beta cells, thereby slowing down the progression of the disease.
According to NICE's decision-making data, a single 14-day course of intravenous teplizumab could delay a type 1 diabetes diagnosis by an average of approximately two years. This delay offers a critical window for patients and their families, potentially reducing the burden of managing the condition and preventing serious complications associated with early diagnosis.
It is estimated that around 600 people in England will be eligible for this treatment. To identify these individuals, healthcare professionals will need to assess those aged eight and over who are in stage 2 of type 1 diabetes – meaning they have two or more type 1 diabetes-related autoantibodies and abnormal blood glucose regulation, but are not yet symptomatic.
Professor Jonathan Benger, Chief Medical Officer at NICE, highlighted the significance of this approval, stating that it represents a major step forward in the management of type 1 diabetes. He noted that delaying the onset, even by two years, can have a substantial positive impact on a person's life, reducing the burden of managing the condition and potentially preventing serious complications associated with early diagnosis.
This development marks a significant turning point as it is the first disease-modifying treatment for type 1 diabetes approved in the UK. The approval follows the drug's earlier authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA) in June 2023, based on evidence demonstrating its effectiveness and safety profile.